CAMBRIDGE, U.K., July 27, 2005 (PRIMEZONE) -- Astex Therapeutics:
-- AstraZeneca and Astex form their third strategic alliance
-- Alliance focussed on discovery, development and
commercialisation of novel PKB inhibitors for use as anti-cancer
agents
-- AstraZeneca will pay Astex an upfront fee of 2.75 million ($5
million), research funding, milestone payments of up to 150
million ($270 million) and double-digit royalties on commercial
sales
-- Astex retains an option on US co-promotion rights and
collaborating partners
Full press release attached below: http://hugin.info/132636/R/1003844/154279.doc